Strong Earnings Growth
Q4 adjusted after-tax income per diluted share of $1.96, up 51% year-over-year; full-year adjusted after-tax income per diluted share $7.09, up 43% YoY. Adjusted after-tax income for 2025 was $4.0 billion, up 24% YoY.
Robust Underwriting Results
Q4 underwriting income $670 million, up 48% YoY; full-year underwriting income $2.3 billion, up 22% YoY — first year since 2008 to deliver >$2B in underwriting income excluding divested businesses. Q4 accident-year combined ratio (as adjusted) 88.9% (17th consecutive sub-90% quarter); full-year accident-year combined ratio 88.3% and calendar year combined ratio 90.1%.
Premium Growth and New Business Momentum
Global commercial net premiums written grew 3% in Q4 and totaled $17.4 billion for full-year 2025 (+3% YoY; +4% adjusted for prior-year closeout). Global commercial new business grew 9% FY; international new business +10% FY and global specialty +15%; Q4 international new business +14%.
Expense and ROE Improvement
Expense ratio ended 2025 at 31.1%, down 90 basis points YoY with a management target of sub-30% by 2027. Core operating ROE improved to 11.1%, a 200 basis point improvement YoY and the first adjusted ROE above 10% in over a decade.
Improved Investment Income and Yields
Net investment income on an APTI basis was $3.8 billion for the year (up 8% YoY); Q4 APTI net investment income $954 million, up 9% YoY. Average new-money yield on core fixed income was ~4.59% in Q4, +68 basis points YoY; core fixed income contributed $3.1 billion, +17% YoY.
Strong Capital Returns and Balance Sheet Position
Returned $6.8 billion of capital in 2025 (including $5.8 billion of repurchases and $1.0 billion in dividends); quarterly dividend increased 12.5%. Debt outstanding $9 billion with a debt-to-total-capital ratio of 18%. Book value per share $76.44, up 9% YoY; adjusted tangible BVPS $70.37, up 4% YoY.
Favorable Reinsurance Renewals
January 1 reinsurance renewals produced enhanced terms: weighted average risk-adjusted rate decrease in excess of 15% on property catastrophe (substantial savings), improved attachment/return period profile, casualty quota share maintained attractive ceding commission in the low 30s, and added the Everest portfolio on AIG pricing without nominal cost increase.
Strategic Transactions and Partnerships
Convex transaction (~35% equity interest and 9.9% stake in Onyx) plus a 7.5% whole-account quota share in 2026 (rising to 10% in 2027 and 12.5% in 2028) expected to be accretive in 2026. Syndicate 2479 launched with Amwins/Blackstone ($300M capacity). Everest renewal-rights purchase price adjusted to $270M with renewable premium ~ $1.8B and early conversion retention ~75% (~$180M GWP retained in Jan).
GenAI and Digital Progress
Expanded 'Underwriting Assist' to seven additional lines (including Lexington); Lexington submission count increased 26% YoY. Company reached >370,000 submissions toward a 500,000 submission ambition by 2030. GenAI used to accelerate Everest conversion and to support SPV underwriting/analytics.
2026 Growth and Capital Guidance
Company expects low-to-mid-teens net premiums written growth in general insurance for full-year 2026 and intends to repurchase at least $1 billion of common shares in 2026, with additional repurchases likely using proceeds from further Corbridge sell-downs.